BidaskClub cut shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) from a buy rating to a hold rating in a research note published on Thursday.
Other analysts have also recently issued reports about the company. Cantor Fitzgerald set a $10.00 price objective on Bellicum Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, March 13th. Wells Fargo & Co upgraded Bellicum Pharmaceuticals from a market perform rating to an outperform rating and lowered their price objective for the company from $8.30 to $6.85 in a research report on Wednesday, April 11th. Finally, ValuEngine upgraded Bellicum Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, June 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The stock has an average rating of Hold and an average target price of $16.12.
BLCM opened at $7.95 on Thursday. The company has a market cap of $340.84 million, a PE ratio of -2.80 and a beta of 0.55. The company has a current ratio of 6.75, a quick ratio of 6.75 and a debt-to-equity ratio of 0.53. Bellicum Pharmaceuticals has a 1 year low of $5.02 and a 1 year high of $14.49.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.02. The firm had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.08 million. research analysts predict that Bellicum Pharmaceuticals will post -2.35 earnings per share for the current year.
In other Bellicum Pharmaceuticals news, CFO Alan A. Musso sold 6,206 shares of the company’s stock in a transaction on Friday, May 25th. The stock was sold at an average price of $7.97, for a total value of $49,461.82. Following the sale, the chief financial officer now directly owns 26,548 shares in the company, valued at $211,587.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 9.84% of the company’s stock.
A number of large investors have recently made changes to their positions in BLCM. MYDA Advisors LLC bought a new stake in Bellicum Pharmaceuticals in the fourth quarter valued at $118,000. Commonwealth Equity Services LLC grew its position in Bellicum Pharmaceuticals by 52.8% in the first quarter. Commonwealth Equity Services LLC now owns 18,888 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 6,530 shares during the period. LPL Financial LLC bought a new stake in Bellicum Pharmaceuticals in the fourth quarter valued at $140,000. Dynamic Technology Lab Private Ltd bought a new stake in Bellicum Pharmaceuticals in the first quarter valued at $170,000. Finally, Ellington Management Group LLC bought a new stake in Bellicum Pharmaceuticals in the fourth quarter valued at $222,000. Hedge funds and other institutional investors own 43.00% of the company’s stock.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.